Global Glioblastoma Multiforme Treatment Market Assessment, By Drug [Temozolomide, Lomustine, Bevacizumab, Others], By Treatment [Surgery, Radiation, Chemotherapy, Targeted Therapy, Others], By End-user [Hospitals and Clinics, Ambulatory Surgical Centers, Others], By Region, Opportunities and Forecast, 2017-2031F
Global glioblastoma multiforme treatment market size is expected to increase due to the increasing prevalence of glioblastoma multiforme globally, tremendous growth in the pharmaceutical industry, increased research and development activities, and investments by firms, along with collaborative ventures in the industry.
Home>Industry Reports>Global Glioblastoma Multiforme Treatment Market Assessment, Opportunities and Forecast, 2017-2031F
Global glioblastoma multiforme treatment market is projected to witness a CAGR of 8.78% during the forecast period 2024-2031, growing from USD 2.91 billion in 2023 to USD 5.71 billion in 2031. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years.
Growth in global glioblastoma multiforme treatment market is being driven by several factors such as increase in the prevalence of glioblastoma multiforme among the population, the development of innovative therapeutical drugs, and tremendous growth in the pharmaceutical and drug discovery industry. Government initiatives, growing investments by key market players to develop quality and efficient drugs, along with a supportive regulatory framework and collaborative ventures between medical device manufacturers and pharmaceutical companies will further promote the growth of the global glioblastoma multiforme treatment market.
The global glioblastoma multiforme treatment market is significantly undergoing robust growth due to the increasing prevalence of glioblastoma multiforme worldwide. As glioblastoma multiforme is a fast-growing tumor, it is highly essential to get treatment as early as possible to develop any fatal condition. Glioblastoma multiforme treatment methods such as surgery, chemotherapy, and radiation therapy play a crucial role in increasing the life expectancy of the patients. With the growing cases of glioblastoma, there is an increased demand for glioblastoma multiforme treatments due to which many leading players are continuously involved in launching innovative and efficient therapeutical drugs in their cancer treatment product portfolio, which is further propelling the growth of the global glioblastoma multiforme treatment market.
Government initiatives such as granting funds are being initiated to improve research and development in the market to improve medical facilities and provide efficient treatment to the patients. Product launches by key market players, along with increased collaboration activities such as mergers and acquisitions, partnership agreements, and new distribution agreements, drive the global glioblastoma multiforme treatment market. Moreover, several market leaders are undergoing extensive research and development in the market to launch innovative and efficient drugs. Celldex Therapeutics that develops targeted immunotherapy and biologics for the treatment of different types of cancers, announced that its latest drug “Varlilumab” is under clinical trial phase II and is most likely to progress into phase III.
Increasing Prevalence of Glioblastoma Multiforme
The demand for glioblastoma multiforme treatment is increasing significantly due to the rising number of glioblastoma multiforme cases worldwide. Glioblastoma is a leading cause of death among the cancer patients globally, as it is a type of cancer that spreads faster, leading to further health complications. According to an article published in “UT Southwestern Medical Center”, globally, more than 300,000 cases of glioblastoma are diagnosed every year. It states that it is the most common primary malignant brain cancer in the adult population. The survival time for glioblastoma patients is only 15 to 18 months on an average, which further emphasizes the need for research and development to bring efficient treatment process that can increase the survival rate of the patients.
Integration of AI For Expediting Drug Development Process
The use of artificial intelligence in pharmaceutical companies is becoming more significant, due to its huge potential to analyze and generate synthesis pathways during the drug development process, as well as optimize clinical trial designs. Leading players in the glioblastoma multiforme treatment market are continuously involved in using the latest advanced technologies such as artificial intelligence and machine learning to enhance the research and development process, to bring more efficient therapeutic drugs, that can be beneficial in the treatment process of cancer.
For instance, in October 2023, Lantern Pharma Inc., using its AI-based platform, “RADR”, announced that its latest innovative drug “LP-184” for the treatment of glioblastoma was published in the American Association for Cancer Research Journal. It states that LP-184 is a unique small molecule that has highly efficient CNS penetration and low nanomolar activity. With the help of its AI platform RADR, LP-184 is developed in such a way that it can repair damaged DNA. Moreover, it has been proven to be effective for patients with temozolomide resistance.
Radiation Therapy Dominates the Market in Terms of Treatment Methods
Among the different treatment methods for glioblastoma multiforme patients, the application of radiation therapy is increasing significantly. Radiation therapy plays a crucial part in the treatment of glioblastoma multiforme. After the surgical removal of a tumor, radiation therapy alone or in combination with chemotherapy is recommended to kill the remaining cancer cells and limit the growth of cancer cells in the future. Several companies are involved in developing innovative therapeutics to make radiation therapies more efficient. For instance, in December 2023 Shuttle Pharmaceuticals Holdings, Inc. announced application submission of an investigational new drug (IND) to the FDA, to support the company in the development of Ropidoxuridine in the next phase of the clinical trial. Ropidoxuridine is a radiation sensitizer, that is used in radiation therapy to treat glioblastoma multiforme. The innovative approach aims to increase cancer survival rates and prolong a patient’s life.
Hospitals Hold a Major Share in Glioblastoma Multiforme Treatment Market
Among the end-user segment, hospitals account for the highest market share in the global glioblastoma multiforme treatment market. The increasing global population and rising number of hospitals are expected to cater to the demands and the dominance of the segment in the market. Glioblastoma multiform is an aggressive brain tumor that requires different treatments such as surgery, chemotherapy, and radiation therapy. Hospitals provide all these facilities, along with highly qualified surgeons and healthcare providers, which helps smoothen a patient’s journey throughout the entire pathway from diagnosis to follow up and assessment. As the prevalence of cancer such as glioblastoma multiforme is increasing, the demand for hospitals in developed as well as developing countries are increasing, due to which countries are increasing the number of hospitals with advanced diagnostics and treatment facilities. For instance, according to the American Hospital Association, in the year 2023, there were 6,129 hospitals in the United States and more hospitals are under construction. Increased availability of a variety of treatment facilities in the healthcare setting, along with increased trust among the population regarding the reliability and quality of healthcare facilities provided in the hospitals is further driving the growth of hospital segment in the overall market.
North America Holds Significant Market Share
North America dominates global glioblastoma multiforme treatment market, due to its well-developed and highly efficient healthcare infrastructure and availability of the latest and advanced surgical techniques and therapeutical drugs for the treatment of glioblastoma multiforme. The growing prevalence of glioblastoma multiforme among the United States population is the prime factor, that is driving the growth of this market.
For instance, according to the “National Brain Tumor Society”, in the United States, more than 10,000 individuals are affected by glioblastoma multiforme every year and it is estimated that out of all primary malignant brain tumors, 50.1% account for glioblastoma multiforme. The increasing prevalence requires efficient treatment such as surgeries, chemotherapy, and radiation therapy to increase the life span of the patients affected by this disease. Due to this, the demand for glioblastoma multiforme treatment is increasing in North America. Additionally, increased research and development in the market, along with the presence of key market players such as Amgen Inc and Merck & Co. further accelerate the demand for the global glioblastoma multiforme treatment market in the region.
Future Market Scenario (2024 – 2031F)
The global glioblastoma multiforme treatment market is expected to grow in the future, primarily due to increasing prevalence of glioblastoma multiforme worldwide. As the prevalence is increasing, pharmaceutical companies are constantly involved in extensive research and development of innovative therapeutical drugs for the treatment of the disease, along with mergers and acquisitions activities to enhance their product portfolio and expand their global market.
Additionally, the growth of the pharmaceutical industry, increased investments by organizations and government, frequent product launches, and increased FDA approvals by the regulatory bodies further lead to the growth of the global glioblastoma multiforme treatment market. For instance, in January 2024, Roche announced that its latest drug “Atezolizumab” is under clinical trial phase II and is most likely to get the FDA approval soon. The drug is expected to provide efficient treatment to the patients suffering from glioblastoma multiforme. These frequent product launches and favorable regulatory frameworks are further expected to escalate the growth of the market in the forecast period.
Report Scope
“Glioblastoma Multiforme Treatment Market Assessment, Opportunities, and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global glioblastoma multiforme treatment market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031. Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.
|
Report Attribute |
Details |
|
Base Year of the Analysis |
2023 |
|
Historical Period |
2017-2022 |
|
Forecast Period |
2024-2031 |
|
Projected Growth Rate |
CAGR of 8.78% between 2024 and 2031 |
|
Revenue Forecast in 2031 |
USD 5.71 billion |
|
Segments Covered |
Drug, Treatment, End-user |
|
Regions Covered |
North America, Europe, South America, Asia-Pacific, Middle East and Africa |
|
Key Companies Profile |
F. Hoffmann-La Roche Ltd, Amgen Inc., Merck & Co., Inc., Pfizer Inc., Sun Pharmaceutical Industries Limited, Azurity Pharmaceuticals, Inc., Bristol-Myers Squibb Co, Eli Lilly and Company, Lantern Pharma Inc., Karyopharm Therapeutics Inc. |
|
Customization Scope |
15% free report customization with purchase |
|
Pricing and Purchase Options |
Avail the customized purchase options to fulfill your precise research needs |
|
Delivery Format |
PDF and Excel through email (subject to the license purchased) |
In this report, global glioblastoma multiforme treatment market has been segmented into the following categories:
· By Drug
o Temozolomide
o Lomustine
o Bevacizumab
o Others
· By Treatment
o Surgery
o Radiation
o Chemotherapy
o Targeted Therapy
o Others
· By End-user
o Hospitals and Clinics
o Ambulatory Surgical Centers
o Others
· By Region
o North America
o Europe
o Asia-Pacific
o South America
o Middle East and Africa
Key Players Landscape and Outlook
In the glioblastoma multiforme treatment market, pharmaceutical firms and biotechnological companies are consistently forming strategic partnerships and distribution agreements to enhance their productivity and global business. These collaboration activities play a crucial role in propelling the global glioblastoma multiforme treatment market's expansion. The strategic partnerships agreements, enable firms to gain in-depth insights into the market, strategically use each other's resources, markets, and technologies, and invest in research and development activities to bring innovative drug discovers and technological advancements in the treatment methods. Distribution agreements allow companies to expand their market presence globally. These collaborative initiatives promote innovation and expertise in product development, which improves patient health outcomes and contributes to the enduring and robust growth of the global glioblastoma multiforme treatment market.
For instance, in September 2023, Double Bond Pharmaceutical International AB, which is a pharmaceutical company that develops therapeutical drugs against cancer, announced its collaboration with Vivo Biopharma LLC, which is a subsidiary of Sauvie Inc. The collaboration will allow asset purchase and transition agreements for DBP’s SI-053, which is a locally acting formulation of temozolomide, developed for the treatment of glioblastoma. As this latest drug has the potential to increase survival rate in patients suffering from glioblastoma, it is expected that the agreement will provide quality and advanced treatment to cancer patients and will support in elevating the market globally.
Key Players Operating in Global Glioblastoma Multiforme Treatment Market are:
· F. Hoffmann-La Roche Ltd
· Amgen Inc.
· Merck & Co., Inc.
· Pfizer Inc.
· Sun Pharmaceutical Industries Limited
· Azurity Pharmaceuticals, Inc.
· Bristol-Myers Squibb Co
· Eli Lilly and Company
· Lantern Pharma Inc.
· Karyopharm Therapeutics Inc.
Markets and Data’s reports answer the following questions:
· What is the current and future market size of the product/service in question globally or specific to different countries?
· How are the markets divided into different product/service segments and the market size and growth of each segment?
· What is the market potential of different product segments and their investment case?
· How are the markets predicted to develop in the future and what factors will drive or inhibit growth?
· What is the business environment and regulatory landscape specific to the product/service?
If you can't find what you're searching for or have any custom requirements for global glioblastoma multiforme treatment market, you may approach our team at info@marketsandata.com
Table of Contents
1. Research Methodology
2. Project Scope & Definitions
3. Executive Summary
4. Global Glioblastoma Multiforme Treatment Market Outlook, 2017-2031F
4.1. Market Size & Forecast
4.1.1.By Value
4.1.2.By Volume
4.2. By Drug
4.2.1.Temozolomide
4.2.2.Lomustine
4.2.3.Bevacizumab
4.2.4.Others
4.3. By Treatment
4.3.1.Surgery
4.3.2.Radiation
4.3.3.Chemotherapy
4.3.4.Targeted Therapy
4.3.5.Others
4.4. By End-user
4.4.1.Hospital
4.4.2.Ambulatory Surgical Centers
4.4.3.Others
4.5. By Region
4.5.1. North America
4.5.2. Europe
4.5.3. Asia-Pacific
4.5.4. South America
4.5.5. Middle East and Africa
4.6. By Company Market Share (%), 2023
5. Global Glioblastoma Multiforme Treatment Market Outlook, By Region, 2017-2031F
5.1. North America*
5.1.1.Market Size & Forecast
5.1.1.1. By Value
5.1.1.2. By Volume
5.1.2.By Drug
5.1.2.1. Temozolomide
5.1.2.2. Lomustine
5.1.2.3. Bevacizumab
5.1.2.4. Others
5.1.3.By Treatment
5.1.3.1. Surgery
5.1.3.2. Radiation
5.1.3.3. Chemotherapy
5.1.3.4. Targeted Therapy
5.1.3.5. Others
5.1.4.1. Hospital
5.1.4.2. Ambulatory Surgical Centers
5.1.4.3. Others
5.1.5.United States*
5.1.5.1. Market Size & Forecast
5.1.5.1.1. By Value
5.1.5.1.2. By Volume
5.1.5.2. By Drug
5.1.5.2.1. Temozolomide
5.1.5.2.2. Lomustine
5.1.5.2.3. Bevacizumab
5.1.5.2.4. Others
5.1.5.3. By Treatment
5.1.5.3.1. Surgery
5.1.5.3.2. Radiation
5.1.5.3.3. Chemotherapy
5.1.5.3.4. Targeted Therapy
5.1.5.3.5. Others
5.1.5.4. By End-user
5.1.5.4.1. Hospital
5.1.5.4.2. Ambulatory Surgical Centers
5.1.5.4.3. Others
5.1.6.Canada
5.1.7.Mexico
*All segments will be provided for all regions and countries covered
5.2. Europe
5.2.1.Germany
5.2.2.France
5.2.3.Italy
5.2.4.United Kingdom
5.2.5.Russia
5.2.6.Netherlands
5.2.7.Spain
5.2.8.Turkey
5.2.9.Poland
5.3. Asia-Pacific
5.3.1.India
5.3.2.China
5.3.3.Japan
5.3.4.Australia
5.3.5.Vietnam
5.3.6.South Korea
5.3.7.Indonesia
5.3.8.Philippines
5.4. South America
5.4.1.Brazil
5.4.2.Argentina
5.5. Middle East & Africa
5.5.1.Saudi Arabia
5.5.2.UAE
5.5.3.South Africa
6. Market Mapping, 2023
6.1. By Drug
6.2. By Treatment
6.3. By End-user
6.4. By Region
7. Macro Environment and Industry Structure
7.1. Demand Supply Analysis
7.2. Import Export Analysis
7.3. Value Chain Analysis
7.4. PESTEL Analysis
7.4.1.Political Factors
7.4.2.Economic System
7.4.3.Social Implications
7.4.4.Technological Advancements
7.4.5.Environmental Impacts
7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5. Porter’s Five Forces Analysis
7.5.1.Supplier Power
7.5.2.Buyer Power
7.5.3.Substitution Threat
7.5.4.Threat from New Entrant
7.5.5.Competitive Rivalry
8. Market Dynamics
8.1. Growth Drivers
8.2. Growth Inhibitors (Challenges and Restraints)
9. Regulatory Framework and Innovation
9.1. Clinical Trials
9.2. Patent Landscape
9.3. Regulatory Approvals
9.4. Innovations/Emerging Technologies
10. Key Players Landscape
10.1. Competition Matrix of Top Five Market Leaders
10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4. SWOT Analysis (For Five Market Players)
10.5. Patent Analysis (If Applicable)
11. Pricing Analysis
12. Case Studies
13. Key Players Outlook
13.1. F. Hoffmann-La Roche Ltd
13.1.1. Company Details
13.1.2. Key Management Personnel
13.1.3. Products & Services
13.1.4. Financials (As reported)
13.1.5. Key Market Focus & Geographical Presence
13.1.6. Recent Developments
13.2. Amgen Inc.
13.3. Merck & Co., Inc.
13.4. Pfizer Inc.
13.5. Sun Pharmaceutical Industries Limited
13.6. Azurity Pharmaceuticals, Inc.
13.7. Bristol-Myers Squibb Co
13.8. Eli Lilly and Company
13.9. Lantern Pharma Inc.
13.10. Karyopharm Therapeutics Inc.
*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.
14. Strategic Recommendations
15. About Us & Disclaimer
List of Figures
Figure 1. Global Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 2. Global Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 3. Global Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 4. Global Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 5. Global Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 6. Global Glioblastoma Multiforme Treatment Market Share (%), By Region, 2017-2031F
Figure 7. North America Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 8. North America Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 9. North America Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 10. North America Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 11. North America Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 12. North America Glioblastoma Multiforme Treatment Market Share (%), By Country, 2017-2031F
Figure 13. United States Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 14. United States Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 15. United States Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 16. United States Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 17. United States Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 18. Canada Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 19. Canada Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 20. Canada Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 21. Canada Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 22. Canada Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 23. Mexico Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 24. Mexico Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 25. Mexico Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 26. Mexico Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 27. Mexico Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 28. Europe Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 29. Europe Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 30. Europe Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 31. Europe Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 32. Europe Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 33. Europe Glioblastoma Multiforme Treatment Market Share (%), By Country, 2017-2031F
Figure 34. Germany Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 35. Germany Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 36. Germany Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 37. Germany Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 38. Germany Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 39. France Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 40. France Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 41. France Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 42. France Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 43. France Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 44. Italy Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 45. Italy Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 46. Italy Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 47. Italy Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 48. Italy Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 49. United Kingdom Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 50. United Kingdom Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 51. United Kingdom Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 52. United Kingdom Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 53. United Kingdom Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 54. Russia Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 55. Russia Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 56. Russia Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 57. Russia Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 58. Russia Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 59. Netherlands Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 60. Netherlands Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 61. Netherlands Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 62. Netherlands Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 63. Netherlands Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 64. Spain Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 65. Spain Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 66. Spain Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 67. Spain Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 68. Spain Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 69. Turkey Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 70. Turkey Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 71. Turkey Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 72. Turkey Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 73. Turkey Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 74. Poland Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 75. Poland Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 76. Poland Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 77. Poland Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 78. Poland Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 79. South America Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 80. South America Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 81. South America Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 82. South America Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 83. South America Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 84. South America Glioblastoma Multiforme Treatment Market Share (%), By Country, 2017-2031F
Figure 85. Brazil Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 86. Brazil Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 87. Brazil Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 88. Brazil Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 89. Brazil Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 90. Argentina Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 91. Argentina Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 92. Argentina Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 93. Argentina Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 94. Argentina Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 95. Asia-Pacific Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 96. Asia-Pacific Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 97. Asia-Pacific Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 98. Asia-Pacific Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 99. Asia-Pacific Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 100. Asia-Pacific Glioblastoma Multiforme Treatment Market Share (%), By Country, 2017-2031F
Figure 101. India Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 102. India Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 103. India Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 104. India Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 105. India Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 106. China Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 107. China Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 108. China Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 109. China Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 110. China Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 111. Japan Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 112. Japan Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 113. Japan Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 114. Japan Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 115. Japan Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 116. Australia Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 117. Australia Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 118. Australia Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 119. Australia Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 120. Australia Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 121. Vietnam Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 122. Vietnam Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 123. Vietnam Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 124. Vietnam Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 125. Vietnam Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 126. South Korea Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 127. South Korea Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 128. South Korea Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 129. South Korea Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 130. South Korea Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 131. Indonesia Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 132. Indonesia Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 133. Indonesia Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 134. Indonesia Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 135. Indonesia Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 136. Philippines Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 137. Philippines Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 138. Philippines Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 139. Philippines Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 140. Philippines Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 141. Middle East & Africa Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 142. Middle East & Africa Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 143. Middle East & Africa Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 144. Middle East & Africa Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 145. Middle East & Africa Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 146. Middle East & Africa Glioblastoma Multiforme Treatment Market Share (%), By Country, 2017-2031F
Figure 147. Saudi Arabia Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 148. Saudi Arabia Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 149. Saudi Arabia Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 150. Saudi Arabia Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 151. Saudi Arabia Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 152. UAE Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 153. UAE Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 154. UAE Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 155. UAE Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 156. UAE Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 157. South Africa Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
Figure 158. South Africa Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
Figure 159. South Africa Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
Figure 160. South Africa Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
Figure 161. South Africa Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
Figure 162. By Drug Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 163. By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 164. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
List of Tables
Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects
Frequently Asked Questions
Who are the key players operating in global glioblastoma multiforme treatment market?
What are the regions covered in the final report of global glioblastoma multiforme treatment market?
What are the major drivers influencing the growth of global glioblastoma multiforme treatment market?
What is the market size and growth rate of global glioblastoma multiforme treatment market?
See Related Reports
Global Electric Vehicle Battery Swapping Market Assessment, Opportunities and Forecast, 2017-2031F
Increased EV adoption, new fast and bi-directional charging, and extended research and development are expected to fuel the market growth during the forecast period.....Read More
Published on
May 2024
4,500
Global Adaptive Cruise Control (ACC) Market Assessment, Opportunities and Forecast, 2017-2031F
Advanced vehicle security dynamics along with the higher adoption of EVs are anticipated to fuel the market growth.....Read More
Published on
May 2024
4,500
Global Automotive Multi-camera System Market Assessment, Opportunities and Forecast, 2017-2031F
Global automotive multi-camera system market is expected to experience growth due to the rising adoption of ADAS in vehicles, increasing the demand for improved safety features, electric vehicles, and autonomous driving.....Read More
Published on
May 2024
4,500
Global Apple Cider Vinegar Market Assessment, Opportunities and Forecast, 2017-2031F
Global apple cider vinegar market is expected to experience growth due to rising use of apple cider vinegar due to its health concerns.....Read More
Published on
May 2024
4,500
Purchase Options
USD ($)
i
3,000
i
4,500
i
5,700
i
8,200
Tired of Searching?
Looking for Customization?
Some other doubt?
Need insights from a cohort?
REACH US
